No Data
No Data
NanoViricides Restructures Agreements to Alleviate Financial Stress
Express News | EF Hutton Reiterates Buy on Nanoviricides, Maintains $6.5 Price Target
Nanoviricides Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/16/2024 470.18% EF Hutton → $6.5 Reiterates Buy → Buy 06/01/2023 360.53% EF Hutton → $5.25 Assumes → Bu
Nanoviricides Q2 EPS $(0.18) Down From $(0.15) YoY; As Of December 31, 2023, We Had Cash And Cash Equivalent Current Assets Balance Of Approximately $5.31M. Additional Agreements Have Resulted In A Further Approximately $2.5M Available Cash
Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.18) per share. This is a 20 percent decrease over losses of $(0.15) per share from the same period last year.
NanoViricides GAAP EPS of -$0.18
NanoViricides Has Filed Its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarte
No Data